Symbolbild · KI-generiert
Avicanna Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Avicanna is an international biopharmaceutical company specializing in the commercialization of proprietary and evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has established scientific and medical affairs platforms that support its four commercial stage business pillars and have resulted in the commercialization of more than fifty finished products. Medical Cannabis formulary (RHO Phyto¿): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto¿ is an established brand in Canada currently available nationwide across several channels and expanding into new international markets. Medical cannabis care platform (MyMedi.ca): MyMedi.
Company description as published by the issuer via TMX Money.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Avicanna Inc. | AVCN | TSX | 12 Mio. USD |
| KDA Group Inc. | KDA | TSXV | 12 Mio. USD |
| VVT Med Inc. | VVTM | TSXV | 11 Mio. USD |
| Pharmacielo Ltd. | PCLO | TSXV | 11 Mio. USD |
| Pharmala Biotech Holdings Inc. | MDMA | CSE | 12 Mio. USD |
| Aurora Spine Corporation | ASG | TSXV | 11 Mio. USD |
| Izotropic Corporation | IZO | CSE | 12 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.